Chiral Nanoparticle Microfluidic Device for Exosome Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting cancer-associated extracellular vesicles, such as exosomes, in biological fluids are complex, time-consuming, and require extensive sample preparation, limiting their utility in timely cancer diagnosis.
Innovation Solution
A microfluidic device with a microfluidic channel coated with chiral nanoparticles, specifically gold nanoparticles functionalized with targeting ligands like Annexin V, which can bind to cancer-associated exosomes, enabling rapid and accurate detection through circular dichroism spectroscopy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional protein profiling methods (western blot, ELISA) are used to detect exosomes, then detection accuracy can be achieved, but the process requires complex multi-step purification procedures and large amounts of proteins, making it time-consuming and unsuitable for timely diagnosis
Solution Approach 1:
The patent combines multiple functions into a single microfluidic device: exosome capture, protein extraction, and detection occur simultaneously in one integrated platform. The microfluidic channel incorporates capture surfaces with specific antibodies that directly bind exosome proteins, eliminating the need for separate purification steps while maintaining detection accuracy.
Solution Approach 2:
The microfluidic device is designed to perform multiple operations universally: it can capture different types of exosomes, extract various proteins, and conduct detection all within the same system. This multi-functional design reduces procedural complexity while preserving measurement precision across different analytes.
2Loss of information
If conventional protein profiling methods are used, then detailed protein analysis can be obtained, but large amounts of proteins and extensive sample preparation are required, limiting timely diagnosis capability
Solution Approach 1:
The microfluidic device extracts only the specific protein information needed for diagnosis from the complex exosome sample, rather than requiring analysis of all proteins. Capture surfaces are functionalized with antibodies that selectively bind to target proteins, extracting relevant information while discarding unnecessary components, thus reducing both time and sample requirements.
Solution Approach 2:
The device performs preliminary capture and concentration of target proteins on the microfluidic channel surface before detection. This preliminary action enriches the analyte of interest and prepares it for rapid detection, eliminating the need for extensive sample preparation and reducing overall diagnosis time while preserving protein information.
3Power
If surface-enhanced Raman scattering (SERS) is used for exosome detection, then signal amplification and real-time detection capabilities are achieved, but considerable sample pre-processing and data post-processing are required, making the process lengthy
Solution Approach 1:
The patent replaces complex mechanical pre-processing and post-processing steps with a streamlined microfluidic detection system. The microfluidic device directly captures and detects exosomes using optical methods, substituting lengthy sample preparation and data processing procedures with integrated real-time measurement, thus maintaining signal amplification while improving detection speed.
4Reliability
If surface plasmon resonance (SPR) assay using periodic nanohole arrays is used, then exosome capture capability is achieved, but sophisticated fabrication process and optical limitations make it difficult to implement in inexpensive devices
Solution Approach 1:
The patent changes the physical parameters of the capture surface from complex periodic nanohole arrays to simpler microfluidic channel surfaces functionalized with antibodies. This parameter change maintains exosome capture capability through specific antibody-exosome binding while dramatically simplifying the fabrication process, enabling manufacture in inexpensive devices without sophisticated fabrication facilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device allows for the rapid isolation and detection of cancer-associated exosomes directly from blood plasma, providing a sensitive and specific method for cancer diagnostics and mutation profiling, potentially enabling liquid biopsy applications.
Implementation Method 1
chiral nanoparticles each comprise a light-absorbing material... to measure a first level of at least one of a magnitude of circular dichroism or a peak wavelength
Implementation Method 2
a microfluidic platform for exosome capture can also be utilized for surface plasmon resonance (SPR) assay using periodic nanohole arrays
Implementation Method 3
The plurality of chiral nanoparticles also each comprise a targeting ligand associated with the plurality of chiral nanoparticles that is capable of binding to a bioactive target analyte in a biological fluid sample
Data Source
AI summary
Microfluidic devices including a microfluidic channel with at least one surface having a plurality of chiral nanoparticles disposed thereon include a light-absorbing material (e.g., gold) and a targeting ligand capable of binding to a bioactive target analyte in a biological fluid sample. The bioactive target analyte can indicate presence of cancerous cells or mutated proteins in the biological fluid sample taken from a subject. Chiral gold nanoparticle layer-by-layer assembled onto a microfluidic device can rapidly isolate and profile cancer-associated exosomes directly from blood plasma using their own unique chiral signal. Exosomes from lung cancer patients can be distinguished from healthy donor exosomes by chiroptical spectroscopic signatures of biomolecular components. Mutation/deletion of epidermal growth factor receptor are also characterized, suggesting the possibility for in-depth mutation profiling in addition to cancer diagnostics. Methods of detecting bioactive target analytes and making the microfluidic devices are also provided.